Should we monitor platelet function during antiplatelet therapy?

Heart

Volumn 94, Issue 6, 2008, Pages 685-687

  Hjemdahl, Paul ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; GLUCOSE; INSULIN; THROMBIN; THROMBOXANE; TICLOPIDINE;

BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; OXIDATIVE STRESS; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RISK REDUCTION; SHEAR STRESS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; UNSPECIFIED SIDE EFFECT;

BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS;

EID: 44349127858     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.135194     Document Type: Editorial

References (16)

1. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-83.
2. Eshagian S, Kaul S, Shah P, et al. Role of clopidogrel in managing atherothrombotic cardiovascular disease. Ann Intern Med 2007;146:434-41.
3. Patrono C, Rocca B. Drug insight: aspirin resistance - fact or fiction? Nat Clin Pract Cardiovasc Med 2007;4:42-50.
4. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 2007;120:311-21.
5. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007;5(Suppl 1):230-7.
6. Geisler T, Kapp M, Göhring-Frischolz K, et al. Residual platelet activity is increased in clopidogrel-and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008;94:743-7.
7. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic actions of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007;109:2285-92.
8. Harrrison P, Frelinger AL, Furman MI, et al. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007;120:323-36.
9. Lordkipanidzé M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-8.
10. Fontana P, Nolli S, Reber G, et al. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006;4:813-9.
11. Snoep JD, Hovens MMC, Eikenboom JCJ, et al: Association of laboratory-defined aspirin resistance with a high risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007;167:1593-9.
12. Perneby C, Wallén NH, Rooney C, et al: Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006;95:652-8.
13. O'Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies - clopidogrel: does one size fit all? Circulation 2006;114;e601-6.
14. Montescalot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading dose in patients with non-ST-segment elevation acute coronary syndromes. JACC 2006;48:931-8.
15. Snoep JD, Hovens MMC, Eikenboom JCJ, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221-31.
16. Schwartz KA, Schwartz DE, Ghosheh K, et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005;95:973-5.